Clinical trial NCT05193370: Angiotensin II vs. Vasopressin in Septic Shock
Official title: A Randomized Controlled Pilot Trial of Angiotensin II Versus Vasopressin as Second-line Vasopressor in the Treatment of Septic Shock
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Septic Shock
Keywords: septic shock
vasopressor
angiotensin II
vasopressin
renin
randomized controlled trial
Lead sponsor: University of New Mexico
Sponsor class: OTHER
Collaborators: name: La Jolla Pharmaceutical Company
name: National Center for Advancing Translational Sciences (NCATS)
First posted: 2022-01-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: single-center, open-label pragmatic randomized controlled pilot trial using block randomization
Primary purpose: TREATMENT

Brief summary: This will be a randomized controlled unblinded pragmatic single-center pilot trial of the use of vasopressin vs. angiotensin II as a second-line vasopressor in patients with septic shock and persistent hypotension despite moderate-to-high doses of norepinephrine.

Detailed description: Sepsis affects \>1 million Americans yearly and, when septic shock ensues, is associated with high morbidity and mortality. Though first-line norepinephrine is standard of care, there are limited prospective data to guide the choice of additional vasopressors in septic shock. While more studies are needed, preliminary data suggest that the vasopressor angiotensin II (AngII) may improve outcomes in septic shock.

This study is a pilot randomized controlled trial (RCT) comparing AngII (intervention) and vasopressin (standard of care) as second-line vasopressors in septic shock. The goal is to demonstrate feasibility of a large multicenter RCT and eventually to demonstrate that AngII use improves important endpoints (e.g., mortality, need for organ support) in all or certain subsets of patients with septic shock.

Furthermore, there are no biomarkers currently available and validated to guide the choice of vasopressor therapy in septic shock. In this study the investigators will investigate serum renin as such a biomarker. Renin has been shown in preliminary studies to accurately predict mortality in septic shock, outperforming lactate, and to predict beneficial response to AngII. The investigators aim to validate the use of renin as a biomarker in septic shock and prove its utility in guiding vasopressor selection, with the goal of incorporating renin levels at specified time points and/or change in renin levels into an algorithm used to select patients for AngII therapy in the subsequent large multicenter RCT.

Eligibility criteria: Inclusion Criteria:

* 1. Adult patients ≥18 years-old with vasodilatory shock refractory to norepinephrine monotherapy, defined as those who require ≥0.2 mcg/kg/min to maintain a MAP between 65-70 mmHg. Patients will be screened once they require ≥0.1 mcg/kg/min of norepinephrine and, if eligible, may be consented at this point. Study drug (angiotensin II or vasopressin) will be initiated once norepinephrine dose reaches ≥0.2 mcg/kg/min for at least 30 minutes.
* 2. Patients are required to have central venous and arterial catheters present, and they are expected to remain in place for at least the initial 72 hours of study.
* 3. Patients are required to have an indwelling urinary catheter present, and it is expected to remain in place for at least the 72 hours of study.
* 4. Patients must have received 20-30 mL/kg of crystalloid over the previous 24-hour period, as clinically appropriate, and no longer be fluid responsive as per UNMH protocol. By UNMH protocol, lack of fluid responsiveness is considered a failure to increase stroke volume, stroke volume index, cardiac output, or cardiac index (typically measured by non-calibrated pulse contour analysis using a FloTrac device) by at least 10% after a 500-mL crystalloid bolus or a passive leg raise. Patients for whom the treating physicians feel that 20 mL/kg of crystalloid may be clinically inappropriate can qualify for the study if the reason for withholding further IV fluids is documented.
* 5. Patient or (in patients unable to consent) legal authorized representative (LAR) is willing and able to provide written informed consent and comply with all protocol requirements.
* 6. Approval from the attending physician and clinical pharmacist conducting the study.

Exclusion Criteria:

* 1. Patients who are \< 18 years of age.
* 2. Patients diagnosed with acute occlusive coronary syndrome requiring intervention and/or cardiogenic shock.
* 3. Patients with or suspected to have abdominal aortic aneurysm or aortic dissection.
* 4. Acute stroke.
* 5. Patients with acute mesenteric ischemia or those with a history of mesenteric ischemia.
* 6. Patients with known Raynaud's phenomenon, systemic sclerosis, or vasospastic disease.
* 7. Patients on veno-arterial (VA) ECMO.
* 8. Patients with liver failure with a Model for End-Stage Liver Disease (MELD) score of ≥30.
* 9. Patients with burns covering \>20% of total body surface area.
* 10. Patients with a history of asthma or COPD with active acute bronchospasm or (if not mechanically ventilated) with an acute exacerbation of their asthma/COPD requiring the use of inhaled bronchodilators.
* 11. Patients requiring more than 500 mg daily of hydrocortisone or equivalent glucocorticoid medication as a standing dose.
* 12 Patients with an absolute neutrophil count (ANC) of \< 1,000/mm3.
* 13. Patients with hemorrhagic shock OR active bleeding AND an anticipated need (within 48 hours of initiation of the study) for transfusion of \>4 units of packed red blood cells.
* 14. Patients with active bleeding AND hemoglobin \< 7g/dL or any other condition that would contraindicate serial blood sampling.
* 15. Untreated venous thromboembolism (VTE) or inability to tolerate pharmacologic VTE prophylaxis.
* 16. Patients with a known allergy to mannitol.
* 17. Patients with an expected survival of \<24 hours, SOFA score ≥ 16, or death deemed to be imminent or inevitable during the admission
* 18. Either the attending physician or patient and/or substitute decision-maker are not committed to all active treatment (e.g., DNR status).
* 19. Patients who are known to be pregnant at the time of screening. \[All women ≤50 years-old will need a negative serum pregnancy test (serum quantitative beta-hCG) to enroll.\]
* 20. Prisoner status
* 21. Patients who are current participating in another interventional clinical trial.

Primary outcomes:
measure: Percentage of patients who achieve blood pressure (BP) goal (MAP ≥65 mmHg) at 3 hours post-drug initiation
timeFrame: 3 hours
Secondary outcomes:
measure: BP goal at other time points
timeFrame: Up to 72 hours
measure: Time to shock reversal
timeFrame: Up to 72 hours
measure: Change in catecholamine dose
timeFrame: Up to 72 hours
measure: SOFA score
timeFrame: Up to 72 hours
measure: Acute Kidney Injury (AKI)
timeFrame: Up to 28 days
measure: Freedom from Renal Replacement Therapy (RRT)
timeFrame: Up to 28 days
measure: Ventilator-free days
timeFrame: Up to 28 days
measure: ICU LOS
timeFrame: Though study completion, up to 1 year
measure: Hospital LOS
timeFrame: Though study completion, up to 1 year
measure: ICU mortality
timeFrame: Up to 28 days
measure: Hospital mortality
timeFrame: Up to 28 days
measure: Renin levels
timeFrame: Up to 3 hours
measure: Subgroup analyses
timeFrame: Though study completion, up to 1 year
measure: Prespecified Adverse Events
timeFrame: Up to 28 days
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico Health Sciences Center
state: New Mexico
Study officials:
affiliation: University of New Mexico School of Medicine
name: Joao P Teixeira, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of New Mexico School of Medicine
name: Nathan D Nielsen, MD MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hastbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.
citation: Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med. 2018 Jun;46(6):949-957. doi: 10.1097/CCM.0000000000003092.
citation: Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ; VANISH Investigators. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA. 2016 Aug 2;316(5):509-18. doi: 10.1001/jama.2016.10485.
citation: Busse L, Albertson T, Gong M. Outcomes in patients with acute respiratory distress syndrome receiving angiotensin II for vasodilatory shock. Crit Care. 2018;22(Suppl 1):82.
citation: Gleeson PJ, Crippa IA, Mongkolpun W, Cavicchi FZ, Van Meerhaeghe T, Brimioulle S, Taccone FS, Vincent JL, Creteur J. Renin as a Marker of Tissue-Perfusion and Prognosis in Critically Ill Patients. Crit Care Med. 2019 Feb;47(2):152-158. doi: 10.1097/CCM.0000000000003544.
citation: Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, Hastbacka J, Khanna AK, Albertson TE, Tumlin J, Storey K, Handisides D, Tidmarsh GF, Chawla LS, Ostermann M. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial. Am J Respir Crit Care Med. 2020 Nov 1;202(9):1253-1261. doi: 10.1164/rccm.201911-2172OC.